Kinetics of G–CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte‐stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study

Sonnenberg, S; Cortes-Dericks, Lourdes; Freiberger, Petra; Mollnau, Hanke; Zander, Axel R.

doi:10.1111/j.0041-1132.2004.00618.x

Cited by 37 publications

(28 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study looked for differences in HPC mobilization in response to glycosylated Hu or nonglycosylated rHu G-CSF in patients with hematological tumors that are the most frequent candidates for auto-SCT and that require combined mobilization with chemotherapy and G-CSF. The appropriate schedule of mobilization in terms of type of chemotherapy, doses and timing of G-CSF administration has been discussed in several studies, 3,18,[21][22][23][24][25][26] whereas the role of G-CSF glycosylation is still not well defined.…”

Section: Discussionmentioning

confidence: 99%

Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs

Ria

Gasparre

Mangialardi

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs

Ria

Gasparre

Mangialardi

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Blood neutrophils (N ) and G-CSF (G) levels are labeled red and blue, respectively. (B) G-CSF kinetics in volunteers on day 1 (dashed blue line) and day 4 (solid blue line) of sequential G-CSF injections (data adapted from Kroger et al, 2004). Note the high G-CSF levels at day 1 (baseline neutrophil count of ≈5 × 10 6 cells/ml.…”

Section: Empirical Properties Of the Rate Functionsmentioning

confidence: 99%

G-CSF Control of Neutrophils Dynamics in the Blood

2007

View full text Add to dashboard Cite

White blood cell neutrophil is a key component in the fast initial immune response against bacterial and fungal infections. Granulocyte colony stimulating factor (G-CSF) which is naturally produced in the body, is known to control the neutrophils production in the bone marrow and the neutrophils delivery into the blood. In oncological practice, G-CSF injections are widely used to treat neutropenia (dangerously low levels of neutrophils in the blood) and to prevent the infectious complications that often follow chemotherapy. However, the accurate dynamics of G-CSF neutrophil interaction has not been fully determined and no general scheme exists for an optimal G-CSF application in neutropenia. Here we develop a two-dimensional ordinary differential equation model for the G-CSF-neutrophil dynamics in the blood. The model is built axiomatically by first formally defining from the biology the expected properties of the model, and then deducing the dynamic behavior of the resulting system. The resulting model is structurally stable, and its dynamical features are independent of the precise form of the various rate functions. Choosing a specific form for these functions, three complementary parameter estimation procedures for one clinical (training) data set are utilized. The fully parameterized model (6 parameters) provides adequate predictions for several additional clinical data sets on time scales of several days. We briefly discuss the utility of this relatively simple and robust model in several clinical conditions.

show abstract

“…Several groups have reported that progenitor cell collection yield is related to donor weight and that the level of the peripheral blood white cell count and the total number of nucleated cells collected is a predictor of the number of stem cells harvested (Engelhardt et al, 1999;Croop et al, 2000;Kroger et al, 2000). Studies in normal volunteers have suggested that higher doses of G-CSF result in better stem cell mobilisation (Dreger et al, 1994;Engelhardt et al, 1999;Martinez et al, 1999) and that a given dose split into twice daily subcutaneous injections may be preferable to a single injection (Kroger et al, 2004). These are important issues as they may assist in donor selection when more than one donor is available, allow optimisation of the mobilisation regimen and facilitate the logistics of carrying out repeated aphereses.…”

mentioning

confidence: 99%

Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony‐stimulating factor (G‐CSF): impact of age, sex, donor weight and type of G‐CSF used

et al. 2006

View full text Add to dashboard Cite

SummaryMobilised peripheral blood is now the main source of stem cells collected from normal donors. We report our experience of mobilising and collecting 400 normal healthy donors using standardised procedures and techniques. Target recipient doses were reached with one aphaeresis in 63% of donors and with two aphereses in 81% of donors. Approximately 2% of donors yielded such low progenitor values that they were termed 'poor mobilisers'. There were minor effects of donor age, weight and sex and where possible, larger male donors under the age of 55 years should be selected. Two forms of granulocyte colony-stimulating factor (G-CSF) were used at the same dose and no significant difference was seen in the yield of CD34 + cells collected/l of blood processed. However, a greater number of granulocyte-macrophage colony-forming cells were harvested using lenograstim (glycosylated G-CSF) compared with filgrastim (non-glycosylated G-CSF; P ¼ 0AE002). CD34 + cell yields were also measured halfway through the aphaeresis procedure. This was found to be highly predictive of final yield and facilitated distribution of the stem cell product to other centres. The observation that CD34 + yields did not decline in the second half compared with the first half of aphaeresis suggests that the circulating cell numbers are not static.

show abstract

Kinetics of G–CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte‐stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study

Abstract: It is suggested that application of G-CSF twice daily leads to a higher CD34+ cell mobilization owing to a higher minimum serum level and therefore to a more continuous serum baseline level resulting in a more efficient CD34+ cell mobilization.

Cited by 37 publications

References 27 publications

Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs

Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs

G-CSF Control of Neutrophils Dynamics in the Blood

Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony‐stimulating factor (G‐CSF): impact of age, sex, donor weight and type of G‐CSF used

Contact Info

Product

Resources

About